Related Experiment Video
Updated: Jul 30, 2026

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
Published on: October 25, 2015
Stability of methylecgonidine and ecgonidine in sheep plasma in vitro
K B Scheidweiler1, J Shojaie, M A Plessinger
1University of Rochester School of Medicine, Departments of Pathology and Laboratory Medicine, Rochester, NY 14642, USA.
Background:
Crack smokers are exposed to a pyrolysis product, methylecgonidine (MEG), which can be used as an analytical marker for crack smoking. Ecgonidine (EC), a hydrolytic product of MEG, has been identified in urine of crack smokers. MEG undergoes conversion to EC, complicating analysis and perhaps explaining a lack of forensic blood specimens containing MEG.
Methods:
We developed gas chromatography-mass spectrometry (GC-MS) assays for MEG and EC. Plasma was collected from sheep blood containing 0, 0.06, or 0.24 mol/L (0%, 0.25%, or 1%) NaF. MEG was added to these plasmas, and they were incubated at -80, 1, 21, or 37 degrees C to determine whether there were temporal, temperature, or storage effects on MEG stability over 48 h.
Results:
Decreased temperature and increased NaF concentrations limited MEG degradation and EC formation. MEG stored in plasma at -80 degrees C was stable up to 1 month, even in the absence of NaF.
Conclusions:
MEG is stable in sheep plasma collected in commercially available, evacuated blood-collection tubes containing NaF and stored at -80 degrees C. In vitro formation of EC can be minimized with appropriate sample handling, and its in vivo formation may provide a better marker of crack smoking than its parent pyrolysis product.
More Related Videos
07:04A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
02:44Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
Published on: July 26, 2024
Related Concept Videos
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmacodynamic Models: Linear Concentration–Effect Model